TipRanks
Go Ultimate55% OFF

Compare Wuxi Biologics (Cayman) (1FW2) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:1FW2Wuxi Biologics (Cayman)EUR 5.13EUR 20.91B31.1327.93%Strong BuyUnlock the DE:1FW2 analyst price target with TipRanks PremiumDE:1FW2Unlock the DE:1FW2 top-analyst price target with TipRanks Premium
HK:1548Genscript BiotechHKD 35.76HKD 79.58B-14.95116.44%Strong BuyUnlock the HK:1548 analyst price target with TipRanks PremiumDE:1FW2 vs HK:1548Unlock the HK:1548 top-analyst price target with TipRanks Premium
HK:3759Pharmaron Beijing Co., Ltd. Class HHKD 27.20HKD 80.45B41.796.14%Strong BuyUnlock the HK:3759 analyst price target with TipRanks PremiumDE:1FW2 vs HK:3759Unlock the HK:3759 top-analyst price target with TipRanks Premium
HK:1521Frontage Holdings Corp.HKD 1.49HKD 3.04B36.5319.20%―Unlock the HK:1521 analyst price target with TipRanks PremiumDE:1FW2 vs HK:1521Unlock the HK:1521 top-analyst price target with TipRanks Premium
HK:1873Viva Biotech HoldingsHKD 1.26HKD 2.60B12.89-47.03%―Unlock the HK:1873 analyst price target with TipRanks PremiumDE:1FW2 vs HK:1873Unlock the HK:1873 top-analyst price target with TipRanks Premium
HK:2315Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class HHKD 39.28HKD 17.02B38.1647.99%―Unlock the HK:2315 analyst price target with TipRanks PremiumDE:1FW2 vs HK:2315Unlock the HK:2315 top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:1FW2Wuxi Biologics (Cayman)5.131.2130.73%
HK:1548Genscript Biotech35.0217.98105.52%
HK:3759Pharmaron Beijing Co., Ltd. Class H26.981.656.50%
HK:1521Frontage Holdings Corp.1.490.3227.35%
HK:1873Viva Biotech Holdings1.25-1.14-47.70%
HK:2315Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H38.309.0630.98%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts